File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Antioxidant therapy with Salvia miltiorrhiza decreases plasma endothelin-1 and thromboxane B2 after cardiopulmonary bypass in patients with congenital heart disease

TitleAntioxidant therapy with Salvia miltiorrhiza decreases plasma endothelin-1 and thromboxane B2 after cardiopulmonary bypass in patients with congenital heart disease
Authors
Issue Date2003
PublisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/jtcvs
Citation
Journal Of Thoracic And Cardiovascular Surgery, 2003, v. 126 n. 5, p. 1404-1410 How to Cite?
AbstractObjective: The endothelium-derived vasoconstrictor endothelin-1 is increased after cardiopulmonary bypass in children with congenital heart defects. This study determines whether antioxidant therapy with Salvia miltiorrhiza injection, an herb extract containing phenolic compounds, prevents the postoperative increase of endothelin-1. The relationship between endothelin-1 and the endothelium-derived prostacyclin (prostaglandin I2) and thromboxane A2 postoperatively is also investigated. Methods: Twenty children with congenital heart defects and pulmonary hypertension were randomly assigned to group A (placebo control, n = 10) or B (200 mg/kg Salvia miltiorrhiza intravenously after anesthesia induction and at the time of rewarming, respectively; n = 10) before cardiac surgery. Central venous blood samples were taken before operation (T0), 10 (T1) and 30 minutes (T2) after starting cardiopulmonary bypass, 10 (T3) and 30 minutes (T4) after aortic declamping, and 30 minutes (T 55) and 24 hours (T6) after termination of cardiopulmonary bypass. Plasma lipid peroxidation product malondialdehyde, myocardial specific creatine kinase-MB activity, thromboxane B2, and 6-keto-prostaglandin F1α (stable metabolites of thromboxane A2 and prostaglandin I2) were measured. Results: Malondialdehyde increased significantly at T1 in group A and remained significantly higher than in group B thereafter (P < .05). Malondialdehyde in group B did not significantly increase over time. At T5, plasma creatine kinase-MB, thromboxane B2, and endothelin-1 in group B were lower than in group A (P < .05); malondialdehyde correlated significantly with creatine kinase-MB (r = 0.71, P = .0005). At T6, endothelin-1 negatively correlated with the 6-keto-prostaglandin F1α/thromboxane B2 ratio (r = -0.64, P = .0025). Conclusion: Antioxidant therapy reduces myocardial damage and attenuates postoperative vasoactive mediator imbalance.
Persistent Identifierhttp://hdl.handle.net/10722/147205
ISSN
2021 Impact Factor: 6.439
2020 SCImago Journal Rankings: 1.458
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorXia, Zen_US
dc.contributor.authorGu, Jen_US
dc.contributor.authorAnsley, DMen_US
dc.contributor.authorXia, Fen_US
dc.contributor.authorYu, Jen_US
dc.date.accessioned2012-05-29T06:00:46Z-
dc.date.available2012-05-29T06:00:46Z-
dc.date.issued2003en_US
dc.identifier.citationJournal Of Thoracic And Cardiovascular Surgery, 2003, v. 126 n. 5, p. 1404-1410en_US
dc.identifier.issn0022-5223en_US
dc.identifier.urihttp://hdl.handle.net/10722/147205-
dc.description.abstractObjective: The endothelium-derived vasoconstrictor endothelin-1 is increased after cardiopulmonary bypass in children with congenital heart defects. This study determines whether antioxidant therapy with Salvia miltiorrhiza injection, an herb extract containing phenolic compounds, prevents the postoperative increase of endothelin-1. The relationship between endothelin-1 and the endothelium-derived prostacyclin (prostaglandin I2) and thromboxane A2 postoperatively is also investigated. Methods: Twenty children with congenital heart defects and pulmonary hypertension were randomly assigned to group A (placebo control, n = 10) or B (200 mg/kg Salvia miltiorrhiza intravenously after anesthesia induction and at the time of rewarming, respectively; n = 10) before cardiac surgery. Central venous blood samples were taken before operation (T0), 10 (T1) and 30 minutes (T2) after starting cardiopulmonary bypass, 10 (T3) and 30 minutes (T4) after aortic declamping, and 30 minutes (T 55) and 24 hours (T6) after termination of cardiopulmonary bypass. Plasma lipid peroxidation product malondialdehyde, myocardial specific creatine kinase-MB activity, thromboxane B2, and 6-keto-prostaglandin F1α (stable metabolites of thromboxane A2 and prostaglandin I2) were measured. Results: Malondialdehyde increased significantly at T1 in group A and remained significantly higher than in group B thereafter (P < .05). Malondialdehyde in group B did not significantly increase over time. At T5, plasma creatine kinase-MB, thromboxane B2, and endothelin-1 in group B were lower than in group A (P < .05); malondialdehyde correlated significantly with creatine kinase-MB (r = 0.71, P = .0005). At T6, endothelin-1 negatively correlated with the 6-keto-prostaglandin F1α/thromboxane B2 ratio (r = -0.64, P = .0025). Conclusion: Antioxidant therapy reduces myocardial damage and attenuates postoperative vasoactive mediator imbalance.en_US
dc.languageengen_US
dc.publisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/jtcvsen_US
dc.relation.ispartofJournal of Thoracic and Cardiovascular Surgeryen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAntioxidants - Administration & Dosageen_US
dc.subject.meshBiological Assayen_US
dc.subject.meshCardiac Surgical Procedures - Methodsen_US
dc.subject.meshCardiopulmonary Bypass - Adverse Effects - Methodsen_US
dc.subject.meshChemotherapy, Adjuvanten_US
dc.subject.meshChilden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshConfidence Intervalsen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshEndothelin-1 - Blooden_US
dc.subject.meshFemaleen_US
dc.subject.meshHeart Defects, Congenital - Diagnosis - Drug Therapy - Surgeryen_US
dc.subject.meshHumansen_US
dc.subject.meshInfusions, Intravenousen_US
dc.subject.meshIntraoperative Perioden_US
dc.subject.meshMaleen_US
dc.subject.meshMultivariate Analysisen_US
dc.subject.meshPhytotherapy - Methodsen_US
dc.subject.meshPostoperative Complications - Prevention & Controlen_US
dc.subject.meshProbabilityen_US
dc.subject.meshPrognosisen_US
dc.subject.meshSalvia Miltiorrhizaen_US
dc.subject.meshSensitivity And Specificityen_US
dc.subject.meshSeverity Of Illness Indexen_US
dc.subject.meshThromboxane B2 - Blooden_US
dc.subject.meshTreatment Outcomeen_US
dc.titleAntioxidant therapy with Salvia miltiorrhiza decreases plasma endothelin-1 and thromboxane B2 after cardiopulmonary bypass in patients with congenital heart diseaseen_US
dc.typeArticleen_US
dc.identifier.emailXia, Z:zyxia@hkucc.hku.hken_US
dc.identifier.authorityXia, Z=rp00532en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0022-5223(03)00970-Xen_US
dc.identifier.pmid14666012-
dc.identifier.scopuseid_2-s2.0-0344494039en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0344494039&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume126en_US
dc.identifier.issue5en_US
dc.identifier.spage1404en_US
dc.identifier.epage1410en_US
dc.identifier.isiWOS:000186722600028-
dc.publisher.placeUnited Statesen_US
dc.identifier.issnl0022-5223-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats